Pharmacodynamic effects of semorinemab on plasma and CSF biomarkers of Alzheimer's disease pathophysiology

Documenti analoghi

• CSF complement proteins are elevated in prodromal to moderate Alzheimer's disease patients and are not altered by the anti‐tau antibody semorinemab
  di: Cosme Sandoval, et al.
  Pubblicazione: (2024)
• Identification of CSF and brain tau species in Alzheimer's Disease that are highly correlated with tau pathology
  di: Julie Lee, et al.
  Pubblicazione: (2025)
• CSF SNAP‐25 and Neuronal pentraxin 2 associations with cognitive decline in the presence of CSF ptau181/Aβ42 in an at‐risk cohort
  di: Beth M. Planalp, et al.
  Pubblicazione: (2024)
• On the occurrence of Trigonellites in the Upper Chalk at Norwich
  di: Bayfield, T. G.
  Pubblicazione: (1851)
• Children's Library Services for Multicultural Societies in Australia.
  di: Bayfield, Juliana
  Pubblicazione: (1980)